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Abstract
Background & Aims: In ゴグゲ葦p M爾decins Sans Fronti治res estab旭ished the first gen､
era旭 popu旭ation Hepatitis C virus ｪHCVｫ screening and treatment site in Cambodiap 
offering free direct､acting antivira旭 ｪDAAｫ treatments This study ana旭ysed the cost､
effectiveness of this interventions
Methods: Costsp qua旭ity adjusted 旭ife years ｪQALYsｫ and cost､effectiveness of the in､
tervention were projected with a Markov mode旭 over a 旭ifetime horizonp discounted at 
ザ鯵｠years Patient､旭eve旭 resource､use and outcome datap treatment costsp costs of HCV､
re旭ated hea旭thcare and EQ､ズD､ズL hea旭th states were co旭旭ected from an observationa旭 
cohort study eva旭uating the effectiveness of DAA treatment under fu旭旭 and simp旭ified 
mode旭s of care compared to no treatmentq other mode旭 parameters were derived from 
旭iteratures Incrementa旭 cost､effectiveness ratios ｪcost｠QALY gainedｫ were compared to 
an opportunity cost､based wi旭旭ingness､to､pay thresho旭d for Cambodia ｪﾄゴジ芦｠QALYｫs
Results: The tota旭 cost of testing and treatment per patient for the fu旭旭 mode旭 of 
care was ﾄゾゴズｪIQR ﾄ葦葦芦､ゲ葦ザゲｫp reducing to ﾄザゼ葦ｪIQR ﾄザジジ､ジゴゴｫ for the simp旭ified 
mode旭 of cares EQ､ズD､ズL va旭ues varied by fibrosis stager decompensated cirrhosis 
had the 旭owest va旭uep va旭ues increased during and fo旭旭owing treatments The simp旭i､
fied mode旭 of care was cost saving compared to no treatmentp whi旭e the fu旭旭 mode旭 of 
carep a旭though cost､effective compared to no treatment ｪﾄゲ芦ゼ｠QALYｫp cost an addi､
tiona旭 ﾄゲジ ジ芦ズ｠QALY compared to the simp旭ified mode旭p above the wi旭旭ingness､to､pay 
thresho旭d for Cambodias This resu旭t is robust to variation in parameterss
ՊՍ 科 | 科ゴザズゼWALKER ET AL.
ゲ科 |科INTRODUC TION
The Wor旭d Hea旭th Organization ｪWHOｫ estimated that ゼゲ mi旭旭ion peo､
p旭e were infected with the Hepatitis C virus ｪHCVｫ g旭oba旭旭y in ゴグゲズs1 
Most ｪ芦グ鯵ｫ HCV infections are in 旭ow､ and midd旭e､income countries 
ｪLMICｫp2 but fewer than ズ鯵 of these patients are diagnoseds3
HCV is a major contributor to 旭iver cancer and overa旭旭 cancer 
deaths in Cambodia and Asiasジpズ Southeast Asia has the second high､
est burden of vira旭 hepatitis morta旭ity g旭oba旭旭ys1 More than ゲゲ mi旭旭ion 
peop旭e are estimated to have antibodies to HCV in this regionp6 with 
ゴsザ鯵 of Cambodians exposed to HCVsゼ
Direct､acting antivira旭s ｪDAAsｫ offer an effective cure for HCV with 
few side effectss Access to these medicinesp howeverp has been 旭imited 
by their high costp a旭ongside the cost of diagnostics and the infrastruc､
ture required for sca旭ing up treatmentsザp芦 In Cambodiap hea旭thcare expen､
diture per capita is 旭ow ｪﾄ葦ゾ in ゴグゲゴｫq of this 葦グ鯵 comes from patient 
out of pocket expensess9 Despite 旭imited fundingp ongoing government 
hea旭th initiatives provide tubercu旭osisp ma旭aria and HIV｠AIDS treatment 
free at the point of cares Howeverp there is no nationa旭 HCV strategyp 
with procurement of HCV drugs 旭eft entire旭y to the private sectors
In ゴグゲ葦p in co旭旭aboration with the Ministry of Hea旭thp M爾decins Sans 
Fronti治res ｪMSFｫ estab旭ished the first genera旭 popu旭ation HCV testing and 
treatment site in Phnom Penhp Cambodiap offering free DAA treatments 
The initia旭 mode旭 of care for HCV treatmentp based on ゴグゲ葦 European 
Association for the Study of the Liver guide旭inesp11 was subsequent旭y sim､
p旭ified in ゴグゲゼ by reducing the number of patient visits and treatment 
monitoring conductedp with data suggesting this did not adverse旭y affect 
patient outcomes ｪcure rate and incidence of serious adverse eventsｫs10
In this studyp we eva旭uate the cost､effectiveness of both the fu旭旭 
and simp旭ified mode旭s of care imp旭emented by MSFs To our know旭､
edgep this is the first study to conduct a fu旭旭 costing and cost､ef､
fectiveness ana旭ysis of a rea旭､wor旭d HCV treatment intervention in 
a LMICs This inc旭udes Cambodian patient､旭eve旭 data on EQ､ズD､ズL 
hea旭th states for different HCV disease stages and the cost of 
hea旭thcare for HCV､re旭ated 旭iver diseases
ゴ科 |科METHODS
This study eva旭uated the cost､effectiveness of MSFｷs HCV treatment 
program in Cambodia10 in terms of cost per qua旭ity adjusted 旭ife year 
ｪQALYｫ gained using a Markov state､transition mode旭 representing 
the 旭ifetime disease progression of a cohort of HCV､infected patientss 
Mode旭 parametersp hea旭th state va旭ues and costs were based on data 
from the cohort of patients screened and treated as part of the pro､
gramp as we旭旭 as from the 旭iteratures Compared to a counterfactua旭 of 
no treatmentp we eva旭uated two strategies imp旭emented by MSFr the 
initia旭 fu旭旭 mode旭 of care ｪFMCｫp and simp旭ified mode旭 of care ｪSMCｫs
ゴsゲ科|科Setting and mode旭s of care
Patient characteristicsp costs and qua旭ity of 旭ife data were co旭旭ected from 
an observationa旭 cohort study eva旭uating the urea旭､wor旭dv effectiveness 
of DAAs for the treatment of chronic HCV infection in adu旭ts ｪ┕ゲ芦 yearsｫs 
This study was conducted at MSFｷs HCV c旭inicp embedded within the 
gastroentero旭ogy department of the Preah Kossamak Hospita旭 in Phnom 
Penhs10 C旭inic staff were emp旭oyed by MSFp with a sma旭旭 number of 
nurses and doctors seconded from the Ministry of Hea旭ths
The FMC and SMC both inc旭uded processes for HCV diagnosis and 
旭iver disease stagingp fo旭旭owing which patients either began treatmentp 
were referred for further tests to determine e旭igibi旭ity or contro旭 comor､
biditiesp or were determined to be ine旭igib旭e for treatments10 Treatment 
regimens were based on sofosbuvir with dac旭atasvir or sofosbuvir with 
旭edipasvirp with sofosbuvir｠dac旭atasvir used as a pan､genotypic regimen 
in the SMCs Each patient was tested for sustained viro旭ogica旭 response 
at ゲゴ weeks after the end of treatment ｪSVRゲゴｫ to determine if treat､
ment was successfu旭s The SMC used point of care tests ｪSD Bio旭ine and 
GeneXpertｫ for diagnostics whi旭e the FMC used an externa旭 旭ab for ELISA 
and PCR confirmations In the SMCp compared to the FMCp the number 
of sessions where nurse､counse旭旭ors discussed risk factorsp adherence 
and 旭ifesty旭e education with patients were reduced ｪfrom ten to twoｫp 
Conclusions: The simp旭ified mode旭 of care was cost saving compared to no treatmentp 
emphasizing the importance of simp旭ifying pathways of care for improving access to 
HCV treatment in 旭ow､resource settingss
K E Y W O R D S
cost､effectivenessp direct､acting antivira旭 treatmentp hea旭thcare costsp hepatitis Cp 旭ow､income 
popu旭ationp Markov processp treatment costs
Lay Summary
ｨ Access to treatment for Hepatitis C virus ｪHCVｫ has been 
旭imited in 旭ow and midd旭e､income countries because of 
the high cost of drugs and comp旭ex treatment protoco旭s
ｨ M爾decins Sans Fronti治res screened and treated patients for 
HCV in Phnom Penhp Cambodiap with a simp旭e treatment 
protoco旭 with fewer visits ｪthan standard of careｫp point of 
care testing and task shifting from doctors to nursess
ｨ The simp旭e treatment protoco旭 saved money and had 
better outcomes projected over the 旭ifetime of the co､
hort patients compared to if they had not received HCV 
screening and treatments
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genotype testing was e旭iminatedp three b旭ood tests for monitoring during 
treatment were removedp patient visits during treatment were reduced 
from eight to fourp with some tasks shifted from doctors to nurses and 
pharmacists ｪFigure ゲp Tab旭e Sゲｫs The FMC inc旭udes patients initiated on 
treatment from September ゴグゲ葦 through March ゴグゲゼp and the SMC 
inc旭udes patients initiated on treatment from August ゴグゲゼ through Apri旭 
ゴグゲ芦s March to August ゴグゲゼ was a transition phase in which the mode旭 
of care was gradua旭旭y simp旭ifiedｦthis phase is not considered heres
Written consent was obtained from a旭旭 patientss Ethics approva旭 
for this study was obtained from the French Comit爾 de Protection 
des Personnes of Saint､Germain､en､Laye ｪreferencer ゲ葦グジゾｫ and the 
Nationa旭 Ethica旭 Committee for Hea旭th Research of the Cambodian 
MoH ｪreferencer ググズ NECHRｫs Officia旭 permission for this study was 
obtained from the Director of Kossamak Hospita旭s
ゴsゴ科|科Costing methods
The costs of HCV diagnosis and treatment were estimated from 
the providerｷs perspective in ゴグゲゼ US do旭旭arsp using a retrospective 
cohort､based approach over a ゾ､month period ｪSeptember ゴグゲ葦･
May ゴグゲゼｫs Data on costs came from MSFｷs expenditure records and 
price 旭istsp which were a旭旭ocated to activities making up the FMC as 
described abovep with subtota旭s ca旭cu旭ated for c旭inic visitsp 旭abora､
tory testsp DAA and other medicines and diagnosis costss
ゴsゴsゲ科|科Patient､旭eve旭 resource use
Detai旭ed patient､旭eve旭 data on the numbers and types of visits and 
tests undertaken for patients receiving each mode旭 of care were 
co旭旭ected from e旭ectronic individua旭 patient recordss12 Costs of case､
finding were inc旭uded as the cost of testing patients who were not 
found to be chronica旭旭y infecteds Data on the quantity of DAAs and 
other medicines received by each patient during the intervention 
came from pharmacy dispensing recordss Staff time was a旭旭ocated 
for each activity through the use of staff time sheets comp旭eted over 
the course of one week by patient､facing staffp direct observation 
and interviews with staff and according to the number of patient 
interactions in the observation periods
ゴsゴsゴ科|科Va旭uation of resources
Va旭uation of the resources used in the intervention was based on 
detai旭ed financia旭 records provided by MSF using activity､based 
costings The cost per activity within the interventionp for examp旭e 
the base旭ine treatment visitp was estimated as the sum of ingre､
dients ｪTab旭e Sズｫs These ingredientsp such as cost per minute of 
doctor or counse旭旭or time or cost of c旭inic faci旭ities per patient visitp 
were estimated from the financia旭 records during the observation 
period when the FMC was imp旭ementeds Activity cost estimates 
from the FMC during the observation period were adapted to 
estimate the costs of the SMC based on interviews with project 
staff to determine how activities and their ingredients differed be､
tween the mode旭s of cares Unit costs for medicines were derived 
using the ゴグゲゼ MSF Access campaign negotiated costs for DAAs 
and other medicationss The costs of 旭aboratory tests contracted 
outside of the intervention were gathered from hospita旭 price 旭ists 
and from invoices bi旭旭ed to MSF ｪTab旭e S葦ｫs In the base case we 
exc旭ude costs specific to MSF and rep旭ace staff costs for inter､
nationa旭 staff with what 旭oca旭 staff wou旭d be paid by MSF for the 
F I G U R E  ゲ 科 Summary of differences between fu旭旭 ｪtopp b旭ueｫ and simp旭ified ｪbottomp orangeｫ mode旭s of care at each phase of the screening 
and treatment processs Fu旭旭 detai旭s inc旭uded in Tab旭e Sゲ
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same ro旭es More detai旭s on costing methods can be found in the 
supp旭ementary materia旭 ｪMethods Sゲｫs
ゴsゴsザ科|科Cost of hepatitis C､re旭ated disease
Information on patient access to hea旭thcare for HCV､re旭ated 旭iver dis､
ease prior to treatment was gathered through a resource､use ques､
tionnaire administered to a subset ｪn ┎ ゲジジp 旭iver disease stages Fグ､Fジｫ 
of diagnosed patients at their initia旭 visits The questionnaire asked 
patients to reca旭旭 the number of hospita旭 inpatient or outpatient and 
c旭inic visits ｪhea旭th system contactsｫ in the 葦 months prior to coming 
to the MSF c旭inics We assumed that contacts in 葦 months represented 
ha旭f of the annua旭 number of contactss For each type of visitp the pa､
tient was further asked to reca旭旭 the reason and the price paid for the 
most recent visits We use patient､reported costs to represent the cost 
of care in the base case because prior to the MSF programp a旭旭 re旭evant 
costs wou旭d be the responsibi旭ity of the patient ｪMethods Sゴｫs
F I G U R E  ゴ 科 Schematic of Markov 
mode旭 showing how patients progress 
through infection and 旭iver disease 
statess Dashed 旭ines indicate initiation on 
treatments I ┎ infectedq T ┎ on treatmentq 
S ┎ susceptib旭es Base旭ine morta旭ity occurs 
according to cohort agep with equa旭 death 
rates for a旭旭 compartments ｪnot shown in 
figureｫ
TA B L E  ゲ 科 Mode旭 parameters and their distributions for the probabi旭istic sensitivity ana旭ysis
Variable Base-case value Distribution in PSA
Distribution 
parameter(s)a稼 Source
Fibrosis progression ｪannua旭 transition probabi旭ityｫ
Mi旭d fibrosis ｪFグｫ to Mi旭d fibrosis 
ｪFゲｫ
グsゲゲゼ Norma旭 0.005 36
Mi旭d fibrosis ｪFゲｫ to Moderate 
fibrosis ｪFゴｫ
グsグ芦ズ Norma旭 0.004 36
Moderate fibrosis ｪFゴｫ to Moderate 
fibrosis ｪFザｫ
0.121 Norma旭 0.0046 36
Moderate fibrosis ｪFザｫ to Severe 
fibrosis ｪFジｫ
0.115 Norma旭 0.004 36
Fジ to DC 0.039 Beta ゲジs葦p ザ葦グsゴ ｪゾズ鯵 CI 
グsグゴゴ､グsグジ葦ｫ
ザゼ
Fジ or DC to HCC 0.014 Beta ゲsゾp ゲザ葦sゲ ｪゾズ鯵 CI 
グsググゲ葦､ グsグザゾｫ
ザゼ
Fジ to DC after SVR achieved グsグゼグ ｰ Fジ to DC Triang旭e ｬゾズ鯵 CI of base case グsグザ､
グsゴ ｰFジ to DCｭ
グsグググ葦葦p グsググゾゴゴp 
グsググゴゼザ
ザゼpザ芦
Fジ or DC to HCC after SVR 
achieved
グsゴザグ ｰ Fジ or DC to 
HCC
Triang旭e ｬゾズ鯵 CI of base case グsゲ葦､
グsザズ ｰFジ to DCｭ
グsグググゴズ葦p グsグゲザ葦ズp 
0.00322
ザゼpザゾ
Liver､re旭ated morta旭ity ｪannua旭 transition probabi旭ityｫ
DC to 旭iver death 0.130 Beta ゲジゼsグザp ゾ芦ザsゾゼ ｪゾズ鯵 CI 
グsゲゲ､グsゲズｫ
ザゼ
HCC to 旭iver death 0.430 Triang旭e グsジグpグsジジ ザゼ
Vira旭 re､infection ｪannua旭 transition 
probabi旭ityｫ
0 Triang旭e グp グp グsグゲ
SVRゲゴ rate Cohort
Full グsゾ葦芦 Binomia旭 グsゾ葦芦p 葦ゴジ ｪゾズ鯵 CI 
グsゾズグ､グsゾ芦グｫ
Simp旭ified 0.940 Binomia旭 グsゾジグp ゲザゴジ ｪゾズ鯵 CI 
グsゾゴズ､グsゾズゴｫ
Cohort initia旭 age 55.9 Norma旭 10.6 Cohort
aDistribution parameters for PSAr Norma旭r standard deviationq Triang旭er 旭owerp peakp upperq Betar α ｬshapeゲｭp β ｬshapeゴｭq Binomia旭r proportionp samp旭e sizes 
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Patients with fibrosis stage Fグ ｪno 旭iver damageｫ were assumed 
to represent a base旭ine number of hea旭th system contacts ｪvisitsｫ 
for those without 旭iver diseasep with the number of visits for more 
advanced disease states being mode旭旭ed using Poisson regression 
from the questionnaire datas The patient､reported mean cost per 
visit was then mu旭tip旭ied by the mode旭旭ed annua旭 number of visits to 
ca旭cu旭ate the annua旭 cost of 旭iver disease care for each fibrosis stage 
ｪMethods Sゴｫs Estimates of the year旭y cost of decompensated cirrho､
sis ｪDCｫ and hepatoce旭旭u旭ar carcinoma ｪHCCｫ were based on reviews 
of patient records in three hospita旭s ana旭ysed and adjusted through a 
WHO､faci旭itated expert discussions In the base casep we assume that 
ゼグ鯵 of patients with these disease stages access this care based on 
expert opinion ｪMethods Sゴｫs The estimated costs of hea旭thcare are 
assumed to app旭y to infected patients of a旭旭 disease stages and cured 
patients with Fジp DC and HCCs
ゴsザ科|科Simu旭ation mode旭
The costs and outcomes of each treatment strategy were projected 
for a cohort of diagnosed patients using a Markov mode旭 with annua旭 
time stepss The cohort is defined by the number of individua旭s diag､
nosed with chronic HCV infectionp a旭旭ocated to 旭iver disease severity 
categories according to the distribution found among patients who 
had a fibrosis score recordeds The mode旭 schematic ｪFigure ゴｫ shows 
progression characterized by different stages of 旭iver disease sever､
itys The mode旭旭ed hea旭th states inc旭ude stages for METAVIR fibrosis 
scores Fグp Fゲp Fゴp Fザp Fジ ｪcirrhosisｫp14 DC and HCCs Each of the seven 
mode旭旭ed hea旭th states has three possib旭e HCV states ｪinfectedp on 
treatment and cured｠susceptib旭eｫs Patients are mode旭旭ed to receive 
treatment in the first year of the simu旭ationp with the proportion 
treated in each fibrosis stage matching the treatments in the inter､
vention data.
Liver disease､re旭ated morta旭ity ｪassumed to occur in the DC and HCC 
states on旭yｫ and background age､dependent morta旭ity ｪFigure Sゲｫ were 
mode旭旭ed as absorbing hea旭th statess The number of 旭iver transp旭ants per､
formed in Cambodia is neg旭igib旭ep and so was not mode旭旭eds The mode旭 
was imp旭emented in R version ザs葦sゲ using the heemodpackage.ゲズpゲ葦
ゴsザsゲ科|科Disease progression rates
Parameter va旭ues for progression through disease states were 
sourced from previous studies ｪTab旭e ゲｫs Each patient started in 
one of seven 旭iver disease states according to the distribution in 
the cohorts At the end of each cyc旭ep patients either remain in the 
same statep move into a more advanced disease state or die from 
background or HCV､re旭ated morta旭ity ｪFigure ゴｫs In the base case 
we assume there is no re､infection fo旭旭owing curative treatments 
The SVRゲゴ rate was ca旭cu旭ated for the FMC and SMC from patients 
who were due to comp旭ete treatment at 旭east ゲゴ weeks before the 
data export date ｪゲゼ Ju旭y ゴグゲ芦ｫp with those not tested for SVRゲゴ for 
any reasonp inc旭uding 旭oss to fo旭旭ow､up and deathp counted as not 
achieving SVRゲゴ ｪtreatment fai旭ureｫs Patients who fai旭 treatment re､
turn to the infected states and are assumed to face the same risks of 
旭iver disease progression as untreated patientsp whi旭e cured patients 
move to a susceptib旭e compartment in the same 旭iver disease stage 
they were treated ins Being cured stops disease progression in pre､
cirrhotic patients whi旭e it is s旭owed in cirrhotic patientss
ゴsジ科|科Outcomes
The Khmer version of EQ､ズD､ズLゲゼ was used to co旭旭ect hea旭th､re旭ated 
qua旭ity of 旭ife measures for patients ｪジゾザジ tota旭 individua旭sｫ with 
chronic HCV infection prior to treatment initiationp during treatment 
and at the SVRゲゴ visit after treatments Where mu旭tip旭e records were 
avai旭ab旭e for a patient at a given treatment stagep we combined these 
into a sing旭e measure using a time､weighted averages Patients who 
fai旭ed treatment ｪn ┎ 葦ゴｫ were not inc旭uded in the after､treatment 
ana旭ysiss EQ､ズD､ズL measures were stratified by fibrosis stage and 
converted to hea旭th state va旭ues using the EQ､ズD､ズL va旭ue set avai旭､
ab旭e for Indonesiapゲ芦 as this is the c旭osest country in the same Wor旭d 
Bank income group where a va旭ue set is avai旭ab旭es Hea旭th state va旭ues 
for each mode旭 compartment were estimated using a 旭inear mixed､
effects mode旭 with patient as a random effect and fibrosis stage and 
treatment stage as fixed effectss
ゴsズ科|科Cost､effectiveness ana旭ysis
We eva旭uated the cost､effectiveness of the FMC and SMC com､
pared to no HCV treatment in the study popu旭ations The mode旭 was 
run for ゲググ years to cover the fu旭旭 旭ifetime of the cohortp with a 
base旭ine discount rate of ザ鯵 for both future costs and outcomess19 
Cost､effectiveness was eva旭uated in terms of 旭ifetime costs per 
QALY gainedp or the incrementa旭 cost､effectiveness ratio ｪICERｫ 
for each strategys This was compared to an empirica旭 opportunity 
cost､based wi旭旭ingness､to､pay ｪWTPｫ thresho旭d of ﾄゴジ芦 per QALY 
gained20 and to the common旭y used thresho旭d of GDP per capita 
ｪﾄゲゴゼグｫs21
ゴs葦科|科Sensitivity ana旭ysis
We accounted for uncertainty in key parameters by conducting a 
probabi旭istic sensitivity ana旭ysisp in which ゲグググ parameter sets were 
samp旭ed from their statistica旭 distributions ｪTab旭e ゲｫs The cost of 
treatment for each fibrosis stage was varied according to the data in 
a triangu旭ar distribution of the median and inter､quarti旭e range ｪIQRp 
Tab旭e Sジｫs Cost of care was varied in a triangu旭ar distribution accord､
ing to the bootstrapped ゾズ鯵 confidence interva旭 for Fゲ､Fジ ｪTab旭e ゴｫ 
and according to the range of consensus va旭ues for DC and HCCs 
Hea旭th state va旭ues were varied in a triangu旭ar distribution of the 
mean and ゾズ鯵 confidence interva旭 for each fibrosis stage and time 
point ｪTab旭e ザｫs
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In additionp we conducted one､way sensitivity ana旭yses by vary､
ing key parameters in the mode旭 to minimum or maximum va旭ues to 
test mode旭 assumptionss This inc旭uded changing the DAA cost to be 
ﾄゲゴグ per treatment course for every patient instead of varying by 
individua旭p removing or doub旭ing the cost of care for 旭iver diseasep 
using WHO､CHOICE estimates of the cost of care instead of pa､
tient､reported costs for Fグ､Fジ22 ｪMethods Sゴｫ and varying the per､
centage of end stage 旭iver disease patients ｪDC or HCCｫ accessing 
care from ゼグ鯵 to ジグ鯵 or ゲググ鯵s In additionp we ana旭yse the inc旭usion 
of MSF､specific indirect costsp a旭ternative discount rates of グ鯵 or 
ゼ鯵p reducing the time horizon to ゲグ years from ゲググ yearsp a旭旭owing 
for re､infection with HCV at ゲ鯵 or ゲグ鯵 per year ｪexcept for patients 
with HCCｫ and changing the initia旭 age of the cohort to ジズ or 葦ズs 
We eva旭uated how the cost､effectiveness of treatment wou旭d vary 
if screening yie旭ded antibody preva旭ences of ゴsザ鯵 ｪthe nationa旭 es､
timateゼｫp ゲグ鯵 or ザグ鯵p compared to 葦ズ鯵 as observed in the cohorts 
For these sensitivity ana旭ysesp we assumed ゼゴ鯵 chronic infection 
among those that are antibody positivep as found in the cohorts We 
a旭so present resu旭ts using an a旭ternative EQ､ズD､ズL va旭ue set from 
Thailand23 and disabi旭ity va旭ues from the ゴグゲ葦 G旭oba旭 Burden of 
Disease study to estimate hea旭th state va旭ues in the form of disabi旭ity 
adjusted 旭ife years ｪDALYp Tab旭e Sゲグｫs We eva旭uate the effect of pa､
tients having equa旭 treatment rate across a旭旭 fibrosis stagesp match､
ing the overa旭旭 treatment rate in the cohort of 葦ジ鯵p or if the cost 
of treatment is assumed to be the overa旭旭 average mean cost rather 
than varying by fibrosis stages We eva旭uate the resu旭t if core antigen 
testing ｪﾄゴグ｠test24ｫ was used in a one､step screening process ｪno 
antibody testingｫ or to rep旭ace the confirmatory test and if the SVR 
rates for both mode旭s of care were reduced by ゴグ鯵 ｪto ゼズ鯵 and ゼゼ鯵 
for the SMC and FMC respective旭yｫs
ザ科 |科RESULTS
ザsゲ科|科Cohort treatment outcomes
Of ゲズ ゲゲゴ patients screenedp ゼゲザゲ patients were diagnosed 
with chronic HCV ｪジゼ鯵ｫp 葦芦ザゲ referred to care and ジズズグ ｪ葦ジ鯵 of 
diagnosedｫ initiated treatment between ゲゾ September ゴグゲ葦 and ザグ 
Apri旭 ゴグゲ芦 ｪFigure Sジｫs The mean age of those treated was ズズsゾ ｪSD 
ゲグs葦ｫ years and ズゼ鯵 were fema旭es Patients with cirrhosis ｪFジｫp DC 
or HCC made up ザゴs芦鯵 of diagnosed patients and ジジsズ鯵 of treated 
patients ｪTab旭e Sゴｫs
Under the FMC and SMCp 葦ゴジ and ゲザゴジ patients initiated treat､
ment and were fo旭旭owed､up to at 旭east ゲゴ weeks post treatment 
respective旭ys These individua旭s were inc旭uded in the costing and out､
comes ana旭ysisp whi旭e patients treated during the transitiona旭 phase 
between the mode旭s of care were exc旭uded from ana旭ysis ｪFigure 
Sジｫs Characteristics of patients treated under each mode旭 of care are 
presented in Tab旭e Sザs In the FMCp ゾ葦s芦鯵 ｪゾズ鯵 confidence inter､
va旭 ゾズsグ鯵､ゾ芦sグ鯵ｫ of patients achieved SVRゲゴp whi旭e ゾジsグ鯵 ｪゾゴsズ鯵､
ゾズsゴ鯵ｫ achieved SVRゲゴ in the SMCs Treatment regimens were based 
on sofosbuvir with dac旭atasvir in ズ葦鯵 and ゾ芦鯵 of patients in the 
FMC and SMCp respective旭yp with the remaining treatments being 
sofosbuvir with 旭edipasvirs
ザsゴ科|科Costs of HCV treatment
The median tota旭 cost of HCV testing and treatment for the FMC 
was ﾄゾゴズ ｪIQR ﾄ葦葦芦､ゲp葦ザゲｫ and ﾄザゼ葦 ｪIQR ﾄザジジ､ジゴゴｫ for the SMC 
ｪFigure ザp Tab旭e Sジｫs The biggest contributor to the overa旭旭 cost in 
both mode旭s was DAA costsp making up ゴ葦鯵 and ジゴ鯵 of the tota旭 
treatment cost for the FMC and SMC respective旭ys
ザsザ科|科Cost of hepatitis C､re旭ated disease
The number of hea旭th system contacts reported in the resource､
use questionnaire is presented in Tab旭e ゴ and Figure Sゴs The mean 
cost per visit was ﾄゼゴsザジ ｪbootstrapped ゾズ鯵 CI ﾄジゾsザズ､ﾄゲゲグs芦ゲｫ 
and the annua旭 cost of care ranged from ﾄザゾsグ葦 for Fグ to ﾄゴゴ葦sジゴ 
for Fジ ｪTab旭e ゴｫs From the WHO､faci旭itated expert discussionp the 
annua旭 cost of inpatient care for a patient with decompensated cir､
rhosis was ﾄザジゼ ｪvarying from ﾄゴザ葦 to ﾄジズゼ in provincia旭 versus 
nationa旭 hospita旭 settingsｫ and for hepatoce旭旭u旭ar carcinoma was 
TA B L E  ゴ 科 Reported hea旭th system contacts by fibrosis stagep with Poisson mode旭旭ed annua旭 number of hea旭th system contactsp in addition 
to the contacts by an Fグ patient
Disease stage N
Mean, (IQR) reported health system 
contacts in last 6 months
Modelled annual number of health system 
contacts attributable to liver disease, relative to 
Fグ ｪゾズ鯵 CIｫ
Mean annual 
healthcare cost 
ｪゾズ鯵 CIｫ
F0 ゲゼ ゲsグp ｪグ､ゲｫ 0 ﾄグsググ
F1 42 ゲsゴp ｪグ､ゲｫ グsズジ ｪグsグゲ葦､ゲsゲゾｫ ﾄザゾsグ葦 
ｪﾄゾs葦ザ､ﾄ芦ジs葦ズｫ
F2 29 ゲs芦p ｪグ､ゴｫ ゲsゴゴ ｪグsグザゴ､ザsグズｫ ﾄ芦芦sゴズ 
ｪﾄゲゾsゴゼ､ﾄゴゴゼs芦芦ｫ
F3 14 ザsジp ｪグ､葦ｫ ゴsグゼ ｪグsグジ芦､ズsゾジｫ ﾄゲジゾsゼジ 
ｪﾄジ芦sゾザ､ﾄジゲ芦sゴズｫ
F4 ザゼ ゴsザp ｪグ､ザｫ ザsゲザ ｪグsグ葦ズ､ゲグsジズｫ ﾄゴゴ葦sジゴ 
ｪﾄゼザsゾゲ､ﾄゼゴ芦sゲグｫ
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ﾄジゴジ ｪﾄザ葦芦､ﾄズゼ葦ｫs The a旭ternative estimates based on WHO､
CHOICE gave an annua旭 cost of care for Fグ､Fザ of ﾄゴ芦sゴゼ and 
ﾄゴゲ葦sズゲ for Fジs
ザsジ科|科Hea旭th state va旭ues
Hea旭th state va旭ues generated through EQ､ズD､ズL varied by fibro､
sis stage and treatment statuss The hea旭th state va旭ue increased 
by グsグザゾ ｪゾズ鯵 CI グsグザゴ､グsグジ葦ｫ during treatment and グsグ葦芦 ｪゾズ鯵 
CI グsグ葦ゲ､グsグゼズｫ after treatmentp compared to pretreatment 旭eve旭ss 
Patients with DC had the 旭owest hea旭th state va旭uesp グsゲゲ ｪゾズ鯵 CI 
グsグゾグ､グsゲザｫ 旭ower than patients in Fグp whi旭e patients with HCC had 
hea旭th state va旭ues グsグ芦ザ ｪゾズ鯵 CI グsグズグ､グsゲゴｫ 旭ower than patients in 
Fグs Fitted hea旭th state va旭ues for each disease and treatment state 
used in the mode旭 are shown in Tab旭e ザs The hea旭th profi旭es ｪpropor､
tion of individua旭s with each 旭eve旭 for the five dimensionsｫ reported 
in EQ､ズD､ズL are presented in Tab旭es Sゼ､Sゾs
ザsズ科|科Cost､effectiveness
The FMC compared to no treatment was cost､effective ｪﾄゲ芦ゼ｠QALYｫ 
compared to the opportunity cost WTP thresho旭d ｪﾄゴジ芦ｫ and GDP 
thresho旭d ｪﾄゲゴゼグｫs The SMC was cost､saving ｪ┋ﾄゾゲ｠QALYp Tab旭e ジｫ 
compared to no treatments The incrementa旭 benefit of imp旭ementing 
the FMC compared to the SMC costs ﾄゲジ ジ芦ズ｠QALYs These resu旭ts 
are robust to parameter variation in the probabi旭istic sensitivity ana旭､
ysisp with ゾジsグ鯵 of runs for the SMC being cost､saving and ゾゾsゼ鯵 
Disease stage
Health state value
Before treatment During treatment
After treatment 
(cured)
F0 グs芦葦 ｪグs芦ズ､グs芦芦ｫ グsゾグ ｪグs芦ゾ､グsゾゲｫ グsゾザ ｪグsゾゴ､グsゾジｫ
F1 グs芦葦 ｪグs芦ズ､グs芦ゼｫ グsゾグ ｪグs芦ゾ､グsゾゲｫ グsゾザ ｪグsゾゴ､グsゾジｫ
F2 グs芦ズ ｪグs芦ジ､グs芦葦ｫ グs芦ゾ ｪグs芦ゼ､グsゾグｫ グsゾゴ ｪグsゾグ､グsゾザｫ
F3 グs芦ゼ ｪグs芦葦､グs芦ゼｫ グsゾゲ ｪグsゾグ､グsゾゲｫ グsゾジ ｪグsゾザ､グsゾジｫ
F4 グs芦ズ ｪグs芦ジ､グs芦ズｫ グs芦芦 ｪグs芦芦､グs芦ゾｫ グsゾゲ ｪグsゾゲ､グsゾゴｫ
DC グsゼズ ｪグsゼジ､グsゼゼｫ グsゼゾ ｪグsゼゼ､グs芦ゲｫ グs芦ゴ ｪグs芦グ､グs芦ジｫ
HCC グsゼ芦 ｪグsゼズ､グs芦ゲｫ グs芦ゴ ｪグsゼゾ､グs芦ズｫ グs芦ズ ｪグs芦ゴ､グs芦芦ｫ
TA B L E  ザ 科 Hea旭th state va旭ues ｪmean 
and ゾズ鯵 CIｫ by disease stage and 
treatment time point estimated from 
mixed､effects mode旭 with patient as a 
random effect
F I G U R E  ザ 科 Median and interquarti旭e range of overa旭旭 cost of 
treatment ｪtopｫ and median proportion of overa旭旭 cost of treatment 
attributab旭e to different activities ｪbottomｫ under the fu旭旭 and 
simp旭ified mode旭s of cares DAAp direct､acting antivira旭s
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Components of cost of treatment
Strategy
Cost ｪUSDｫ per capita QALY per capita ICER
Total Incremental Total Incremental
Cost/
QALY
No treatment ﾄゲpゴゾ芦 ｦ ゼsジゾ ｦ Dominated
Simp旭ified Mode旭 
of Care
ﾄゲpゲ芦ズ ┋ﾄゲゲザ 芦sゼゴ 1.24 ┋ﾄゾゲ
Fu旭旭 mode旭 of care ﾄゲpズザジ ﾄザズグ 芦sゼズ 0.024 ﾄゲジpジ芦ズ
TA B L E  ジ 科 Incrementa旭 cost､
effectiveness of fu旭旭 and simp旭ified mode旭s 
of care for the base cases Time horizon is 
ゲググ years and discount rate is ザ鯵
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being cost､effective compared to the opportunity cost thresho旭d 
ｪFigure Sザｫs
ザs葦科|科Sensitivity ana旭ysis
When key mode旭 parameters are varied the SMC genera旭旭y remains 
cost､saving compared to no treatment ｪFigure ジｫp whi旭e the FMC is 
never cost､effective compared to the SMC ｪTab旭e Sゲゲｫs The on旭y 
changes which make the SMC not cost､saving are reducing the cost 
of care for a旭旭 HCV､re旭ated 旭iver disease to ﾄグ ｪﾄゴグズ｠QALYｫp using 
WHO､CHOICE costs for Fグ､Fジ 旭iver disease care ｪﾄゴゾ｠QALYｫp in､
creasing re､infection rate to ゲグ鯵 per year ｪﾄザゾ｠QALYｫp or reducing 
screening preva旭ence to ゴsザ鯵 ｪﾄゴ芦｠QALYｫp a旭旭 of which are sti旭旭 cost､
effective compared to the opportunity cost WTP thresho旭d ｪﾄゴジ芦ｫs 
The SMC wou旭d remain cost､saving at an antibody preva旭ence of ザ鯵 
or a re､infection rate up to 葦鯵｠years
ジ科 |科DISCUSSION
Our ana旭yses suggest that an HCV testing and treatment interven､
tion undertaken among the genera旭 popu旭ation in Cambodia cou旭d 
be cost､saving when a simp旭ified mode旭 of care is useds This simp旭i､
fied mode旭 of care provides simi旭ar high rates of cure to the initia旭旭y 
imp旭emented but more cost旭y fu旭旭 mode旭 of cares10 A旭though the fu旭旭 
mode旭 of care resu旭ted in a sma旭旭 incrementa旭 benefit of グsグザ QALYs 
per person compared to the simp旭ified mode旭p this occurred at ap､
proximate旭y trip旭e the cost per treatmentp and was not cost､effective 
compared to the simp旭ified mode旭 of cares
ジsゲ科|科Strengths and 旭imitations
The main strength of this study is the use of detai旭ed data from a 
rea旭､旭ife imp旭ementation of HCV testing and treatment in a LMICp 
inc旭uding a fu旭旭 activity､based costing ana旭ysis instead of expert 
opinion to ca旭cu旭ate the costs of screening and treatments We a旭so 
surveyed patients direct旭y about their hea旭thcare resource use prior 
to seeking HCV treatment in order to estimate the cost of medi､
ca旭 care for patients 旭iving with HCVq to our know旭edge this is the 
first time this has been done in a LMICs Unfortunate旭yp these es､
timates are 旭imited by the 旭ong reca旭旭 period usedp and re旭iance on 
patient､reported expenditures This is 旭ike旭y to be an underestimate 
of the fu旭旭 costs of carep resu旭ting in a conservative ICERs A better 
understanding of the proportion of individua旭s who access different 
F I G U R E  ジ 科 Deterministic sensitivity ana旭ysis showing simp旭ified mode旭 of care ICER compared to no treatment when parameters are 
varied one at a times Text on p旭ot shows new parameter va旭ue where re旭evants So旭id vertica旭 旭ine shows base旭ine ICER of ┋ﾄゾゲ｠QALYp dotted 
旭ine shows ﾄグ｠QALY ｪcost､saving thresho旭dｫp and dashed 旭ine shows opportunity cost thresho旭d for Cambodia ｪﾄゴジ芦｠QALYｫs The fu旭旭 set of 
sensitivity ana旭ysis resu旭ts are shown in Tab旭e Sゲゲ
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旭eve旭s of hea旭thcarep and how this wi旭旭 change in the futurep is crucia旭 
to improving the accuracy of cost､effectiveness estimates for HCV 
treatment.
Another strength is that we direct旭y estimated hea旭th state uti旭ity 
weights for each stage of 旭iver disease and treatment using EQ､ズD､ズL 
questionnaires co旭旭ected from the treated popu旭ations Se旭f､reported 
qua旭ity of 旭ife improved during treatment and at SVRゲゴ as compared 
to base旭inep simi旭ar to what has been observed in a cohort of patients 
treated with DAAs in Japanp25 but with our data adding important 
information for LMICss
A main 旭imitation of this ana旭ysis is thatp because of a 旭ack of 
information on current re､infection risk we did not account for 
changes in disease incidence over time in our ana旭ysiss Howeverp 
as a resu旭t of the advanced age and fibrosis observed in our cohort 
of patientsp it is 旭ike旭y that many individua旭s were infected decades 
ago rather than being at current risk of infection and re､infections 
Inc旭uding a constant re､infection rate made 旭itt旭e difference to the 
resu旭ts
Furthermorep the popu旭ation invo旭ved in this intervention were 
se旭f､se旭ectingp and were therefore high旭y motivated to receive 
treatments The 葦ズ鯵 antibody preva旭ence rate among screened 
patients indicates many were aware or suspected they were in､
fected with HCVs G旭oba旭旭yp fewer than ズ鯵 of those infected with 
HCV are aware of their statusp26 indicating that this high screen､
ing yie旭d is not 旭ike旭y to be maintained once individua旭s who are 
aware of their status have been treated ｪwarehousing effectｫs 
Important旭yp thoughp our projections suggest the intervention 
remains cost saving even if the screening yie旭d reduces to ザ鯵p 
with the estimated preva旭ence for Cambodia being ゴsザ鯵sゼ A new 
sero､preva旭ence study in rura旭 Cambodia found simi旭ar resu旭ts to 
the previous estimatep with ゴs葦鯵 ｪゾズ鯵 CI ゴsザ､ザsグｫ preva旭ence in 
peop旭e ゲ芦 years or o旭derp and ズsゲ鯵 ｪジs葦鯵､ズsゼ鯵ｫ in those ジズ years 
or older.ゴゼ This suggests that targeting screening towards o旭der 
peop旭e wou旭d he旭p the intervention to be cost､savingp whi旭e the 
intervention wou旭d remain high旭y cost､effective ｪﾄゴ芦｠QALYｫ with 
no targetings
The intervention imp旭emented by MSF demonstrates the feasi､
bi旭ity and cost､effectiveness of a genera旭 popu旭ation screening and 
treatment intervention for HCV imp旭emented by an internationa旭 
NGOs If the intervention were expanded by the Ministry of Hea旭th 
or other 旭oca旭 organizationsp costs are 旭ike旭y to be different as MSF 
procured some equipment and consumab旭es outside of Cambodiap 
and a旭though they set 旭oca旭 staff sa旭aries based on competitive 旭oca旭 
ratesp sa旭aries may sti旭旭 vary by organizations To make a detai旭ed im､
p旭ementation p旭an for HCV screening and treatmentp 旭oca旭 organi､
zations can eva旭uate where their costs wi旭旭 differ from MSFs A旭sop 
the 旭andscape of diagnostic too旭s and cost for HCV drugs are both 
rapid旭y changing as countries aim to achieve HCV e旭iminationp so it 
is 旭ike旭y that new techno旭ogies wi旭旭 be avai旭ab旭e for consideration in 
future imp旭ementationss
A旭though we demonstrate that this intervention is cost､sav､
ingp the upfront cost of treatment with the simp旭ified mode旭 of 
care ｪﾄザゲゲ exc旭uding screeningｫ for an estimated ゴゼグ グググ chronic 
infections in Cambodia wou旭d be ﾄ芦ジ mi旭旭ions The fu旭旭 cost of sca旭ing 
up screening and treatment wi旭旭 be high旭y dependent on antibody 
screening yie旭dp which can be maximized through targeting treat､
ment to groups known to be more 旭ike旭y to be infectedp such as the 
o旭der popu旭ationsゴゼ
ジsゴ科|科Comparison with other studies
Previous evidence on the cost､effectiveness of treatment with DAA､
on旭y regimens for HCV in LMIC is 旭imitedp but in agreement with our 
resu旭tss Studies in Egyptゴ芦 and Indiaゴゾ､ザゴ have found HCV screen､
ing and treatment to be cost､savingp and cost､effective in Lebanon33 
and Indonesias34 The WHO Hep C Ca旭cu旭atorp35 which a旭旭ows a user 
to input the cost of treatmentp finds HCV treatment ｪnot inc旭uding 
testingｫ in Cambodia to be cost､effective when defau旭t va旭ues are 
used and cost､saving when input va旭ues from this study are useds 
Howeverp these previous mode旭s do not use data from a rea旭､wor旭d 
interventionp whi旭e ours is the first to use data from a 旭oca旭 treat､
ment intervention to estimate the costs of testingp treatment and 
hea旭thcarep as we旭旭 as qua旭ity of 旭ife uti旭ities for different stages of 
HCV diseases Our ana旭ysis is therefore an important addition to the 
literature.
ジsザ科|科Imp旭ications and conc旭usions
Much of the effort towards expanding access to HCV treatment in 
LMIC has focused on reducing and simp旭ifying the cost of testing 
and DAA medications In this cohortp simp旭ification of the treatment 
pathway quadrup旭ed the number of peop旭e that cou旭d be treated and 
curedp10 reduced the cost of treatment by two､thirds and resu旭ted in 
the intervention becoming cost､savings This remained so even if the 
preva旭ence of HCV was as 旭ow as ザ鯵p suggesting this mode旭 of care 
cou旭d be used to expand screening and treatment across Cambodias 
A旭though our study was imp旭emented by MSFp the Ministry of Hea旭th 
in Cambodia and other LMIC can be empowered by these resu旭ts 
to sca旭e､up HCV treatment access using a simp旭ified mode旭 of care 
re旭ative to standard internationa旭 guide旭iness11 Urgent sca旭e､up of 
treatment access for a旭旭 infected individua旭s is necessary to prevent 
HCV､re旭ated morta旭ity and reach HCV e旭imination as proposed by 
WHOs3
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